Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation
J Curr Ophthalmol
.
2018 Feb 16;30(1):1-2.
doi: 10.1016/j.joco.2018.01.006.
eCollection 2018 Mar.
Author
Hossein Ameri
1
Affiliation
1
USC Roski Eye Institute, Keck School of Medicine, University of Southern California, 1450 San Pablo Street, Los Angeles, CA, 90033, USA.
PMID:
29564403
PMCID:
PMC5859497
DOI:
10.1016/j.joco.2018.01.006
No abstract available
Publication types
Editorial